A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study - Kim, Ung; Lee, Chan-Hee; Jo, Jung-Hwan; Lee, Hyun-Wook; Choi, Yoon-Jung; Son, Jang-Won; Lee, Sang-Hee; Park, Jong-Seon; Shin, Dong-Gu; Kim, Young-Jo; Jeong, Myung-Ho; Cho, Myung-Chan; et al. (Journal of Korean medical science, 2013)
Keywords: Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - therapeutic use; Coronary Artery Disease - drug therapy; Coronary Artery Disease - mortality; Coronary Restenosis - prevention & control; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Original; Paclitaxel - administration & dosage; Paclitaxel - therapeutic use; Percutaneous Coronary Intervention - methods; Prospective Studies; Sirolimus - administration & dosage; Sirolimus - analogs & derivatives; Sirolimus - therapeutic use; Thrombosis; Treatment Outcome; 의학일반; Everolimus-Eluting Stent; Paclitaxel-Eluting Stent